North America Diabetes Care Devices Market size to cross USD 66.8 Billion by 2034

Selbyville, DE. - North America diabetes care devices market was estimated at USD 21 billion in 2024 and is expected to grow from USD 23.3 billion in 2025 to USD 66.8 billion by 2034, at a CAGR of 12.4%, according to the latest report published by Global Market Insights Inc.  

The rising incidence of diabetes, particularly type 2 diabetes, in North America is a major driver for the diabetes care devices market. With over 30 million people living with diabetes in the U.S. alone, the demand for reliable glucose monitors, insulin pumps, and continuous glucose monitoring (CGM) systems is increasing. This growing patient population is fueling the need for more effective and accessible diabetes management tools.  

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 21 billion
• 2025 Market Size: USD 23.3 billion
• 2034 Forecast Market Size: USD 66.8 billion
• CAGR (2025–2034): 12.4%

Regional Insights:

• Largest Market: U.S.
• Fastest Growing Market: Canada

Key Growth Drivers:

1. Technological advancements in diabetes management: Advancements in diabetes care technologies, such as smart glucose meters, wearable insulin pumps, and advanced continuous glucose monitors (CGMs), are driving market growth.  
2. Favorable reimbursement policies: In North America, reimbursement policies for diabetes care devices, particularly under government programs like Medicare, are becoming more favorable.  
3. Growing awareness of diabetes management: There is a significant rise in awareness campaigns educating the public about the importance of managing diabetes effectively.  
4. Aging population: The aging population in North America is contributing to the growth of the diabetes care devices market.  
5. Increased focus on preventative healthcare: In North America, there is a growing emphasis on preventative healthcare and the management of chronic diseases like diabetes.

Key Players:

• Abbott Laboratories led the market with over 14.2% share in 2024.  
• Some of the top players in this market, including Abbott Laboratories, Dexcom, Ascensia Diabetes Care, LifeScan, and F. Hoffmann-La Roche, together held a 35.8% share in 2024.  

Key Challenges

1. High cost of devices: The cost of advanced diabetes care devices, such as continuous glucose monitors (CGMs), insulin pumps, and smart glucose meters, remains a significant barrier.  
2. Insurance coverage and reimbursement issues: Although reimbursement policies for diabetes care devices are improving, insurance coverage remains inconsistent, especially for newer technologies.  
3. Technological complexity and user adoption: Many advanced diabetes care devices, such as CGMs and insulin pumps, come with a steep learning curve.  
4. Data privacy and security concerns: As diabetes care devices become more integrated with smartphones, cloud platforms, and other digital health technologies, concerns over data privacy and security grow.  
5. Limited access in rural areas: In rural areas of North America, there is often limited access to specialized healthcare providers and advanced diabetes care devices.  

Browse key industry insights spread across 110 pages with 32 market data tables and figures from the report, “North America Diabetes Care Devices Market - By Product, By End Use - Regional Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/north-america-diabetes-care-devices-market  

Rising Adoption of Devices

The devices segment held a notable share in 2024, driven by technological advancements. Devices such as continuous glucose monitors (CGMs), insulin pumps, and smart glucose meters have transformed diabetes management by offering real-time monitoring and better control of blood sugar levels. CGMs have become a game-changer for people living with diabetes, providing them with continuous, non-invasive blood glucose tracking.  

Homecare to Gain Traction

The home care segment generated significant revenues in 2024. With a growing preference for managing chronic conditions at home, the demand for home-use diabetes devices such as home glucose monitors, insulin pumps, and portable A1c analyzers has surged. The rise of telemedicine and remote patient monitoring is further accelerating this trend, as patients now have more flexibility in managing their diabetes without frequent visits to healthcare facilities.  

U.S. to Emerge as a Lucrative Region

U.S. diabetes care devices market is poised to grow significantly through 2034, driven by a combination of high disease prevalence, technological advancements, and a growing focus on chronic disease management. With over 30 million Americans living with diabetes, the market has seen a shift from traditional blood glucose meters to more sophisticated technologies such as CGMs, smart insulin pens, and automated insulin delivery systems.  

Major players in the North America diabetes care devices market are Abbott Laboratories, ARKRAY, Ascensia Diabetes Care, B. Braun Melsungen, Becton, Dickinson and Company, BIONIME, DarioHealth, Dexcom, Dr. Reddy’s Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche, Insulet, LifeScan Inc., Medtronic, Nova Biomedical, Novo Nordisk, Platinum Equity Advisors, Sanofi, Sinocare, and Tandem Diabetes Care.  

To strengthen their foothold in the North American diabetes care devices market, companies are adopting several key strategies. First, manufacturers are heavily investing in research and development (R&D) to innovate and create more accurate, user-friendly, and cost-effective devices. This is especially evident in the push toward personalized diabetes management with products like CGMs that provide real-time data synced to mobile apps. Strategic partnerships are also a critical part of the growth strategy. For example, companies are collaborating with insurance providers, healthcare networks, and technology firms to improve device accessibility and ensure that patients have more affordable options.